BioMedomics CoV-SCAN Rapid Antigen Test demonstrated high sensitivity and specificity for numerous SARS-CoV-2 variants, including Omicron and Delta, in a peer-reviewed point-of-care clinical evaluation
Recently published in the highly regarded, peer-reviewed Journal of Clinical Virology Plus, a clinical point-of-care and laboratory trial, performed in conjunction with the Columbia University Irving Medical School, demonstrated the ability of the BioMedomics CoV-SCAN Rapid Antigen Test to detect SARS-CoV-2 variants with high sensitivity and specificity. These results are due to CoV-SCAN’s unique design, using 4 unique antibodies to detect SARS-CoV-2.
In laboratory testing, CoV-SCAN detected 14 variants, including Omicron and Delta, with similar sensitivity to the wild-type virus; CoV-SCAN did not cross-react with any other human coronaviruses.
In clinical point-of-care (POC) testing on 148 individuals over age 2 with symptom onset of less than or equal to 5 days, CoV-SCAN detected SARS-CoV-2 in 87.2% of COVID-19 infected individuals and did not misdiagnose any non-infected individuals. In another 884 asymptomatic individuals, CoV-SCAN detected 85.7% of COVID-19 infected individuals and correctly diagnosed 99.7% of non-infected individuals.
Importantly, CoV-SCAN detected SARS-CoV-2 in greater than 97.2% of patient specimens with CT values < 30, a well-established clinically meaningful cutoff for infectivity.
These results demonstrate that CoV-SCAN should detect SARS-CoV-2 variants, known and unknown, in almost all individuals harboring infectious quantities of COVID-19. Additionally, CoV-SCAN’s high specificity makes it incredibly useful for the early identification of new infectious clusters before they become hotspots.
To read the full article please click here
Comments are closed for this article!